Q2 EPS Estimate for Axsome Therapeutics Decreased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Zacks Research cut their Q2 2025 earnings estimates for shares of Axsome Therapeutics in a note issued to investors on Tuesday, July 1st. Zacks Research analyst R. Department now expects that the company will earn ($1.41) per share for the quarter, down from their prior estimate of ($1.20). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q3 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.87) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.42 EPS, FY2026 earnings at ($0.41) EPS, Q2 2027 earnings at $0.99 EPS and FY2027 earnings at $5.18 EPS.

AXSM has been the subject of a number of other reports. Cantor Fitzgerald raised shares of Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, May 14th. Robert W. Baird upped their price objective on Axsome Therapeutics from $160.00 to $162.00 and gave the company an “outperform” rating in a research note on Tuesday, May 6th. Oppenheimer began coverage on Axsome Therapeutics in a research report on Tuesday, June 3rd. They issued an “outperform” rating and a $185.00 target price for the company. Royal Bank Of Canada lowered their target price on Axsome Therapeutics from $193.00 to $186.00 and set an “outperform” rating on the stock in a research note on Thursday, June 12th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $172.33.

Axsome Therapeutics Trading Up 1.4%

Shares of AXSM stock opened at $105.36 on Thursday. Axsome Therapeutics has a 52-week low of $72.21 and a 52-week high of $139.13. The company has a debt-to-equity ratio of 3.48, a quick ratio of 1.96 and a current ratio of 2.03. The company has a 50-day simple moving average of $106.63 and a two-hundred day simple moving average of $107.56. The company has a market capitalization of $5.19 billion, a price-to-earnings ratio of -18.26 and a beta of 0.46.

Insider Activity

In other news, Director Mark Coleman sold 3,750 shares of the firm’s stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total value of $395,512.50. Following the completion of the transaction, the director directly owned 50,387 shares in the company, valued at approximately $5,314,316.89. This trade represents a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Hunter R. Murdock sold 6,014 shares of the business’s stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $100.12, for a total transaction of $602,121.68. The disclosure for this sale can be found here. Insiders have sold a total of 93,437 shares of company stock worth $9,834,215 over the last ninety days. Company insiders own 22.30% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AXSM. Charles Schwab Investment Management Inc. raised its position in shares of Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock worth $27,755,000 after buying an additional 5,438 shares in the last quarter. Assetmark Inc. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth $52,000. Aigen Investment Management LP purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth $395,000. Arizona State Retirement System raised its position in shares of Axsome Therapeutics by 1.8% in the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock worth $766,000 after buying an additional 164 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth $14,771,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.